NCT03939533 - Study to Monitor Subcutaneous Human Immunoglobulin Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency Diseases | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 17, 2019

Primary Completion Date

January 3, 2022

Study Completion Date

January 3, 2022

Conditions

Primary Immune Deficiency Disorder

Interventions

DRUG

CUTAQUIG

Human normal immunoglobulin

Trial Locations (18)

15241

Octapharma Research Site, Pittsburgh

20815

Octapharma Research Site, Chevy Chase

28801

Octapharma Research Site, Asheville

31707

Octapharma Research Site, Albany

33408

Octapharma Research Site, North Palm Beach

33701

Octapharma Research Site, St. Petersburg

40215

Octapharma Research Site, Louisville

43617

Octapharma Research Site, Toledo

44124

Octapharma Research Site, Mayfield

45231

Octapharma Research Site, Cincinnati

63141

Octapharma Research Site, St Louis

68046

Octapharma Research Site, Papillion

75225

Octapharma Research Site, Dallas

80112

Octapharma Research Site, Centennial

85251

Octapharma Research Site, Scottsdale

92697

Octapharma Research Site, Irvine

93105

Octapharma Research Site, Santa Barbara

98225

Octapharma Research Site, Bellingham